This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Progesterone antagonists (PAs) are compounds that block progesterone (P) action. Wyeth Ayerst is currently developing nonsteroidal PAs as contraceptives in women. It is well known however that P acts in women and nonhuman primates to suppress estrogen-stimulated endometrial cell proliferation. Therefore, there is concern that blockade of P action with PA therapy will lead to unopposed estrogen action and endometrial hyperplasia. Our goal in this study was to test the action of 3 new proprietary nonsteroidal PAs (hereafter coded as PA-1, PA-2, and PA-3) on menstrual cyclicity in macaques and on endometrial cell proliferation in ovariectomized-artificially cycled macaques.
Showing the most recent 10 out of 492 publications